Posted On: 11/06/2015 1:41:06 PM
Post# of 81
$TSRO is a company to keep an eye on.
"The posters describe the homologous recombination deficiency (HRD) analysis being performed on tumor samples from the ongoing Phase 3 NOVA trial of niraparib in patients with ovarian cancer, in addition to preclinical data demonstrating that niraparib crosses the blood brain barrier in animal models and highlighting potential genetic markers of resistance in animal models of small cell lung cancer."
http://investorshangout.com/post/view?id=3322617
"The posters describe the homologous recombination deficiency (HRD) analysis being performed on tumor samples from the ongoing Phase 3 NOVA trial of niraparib in patients with ovarian cancer, in addition to preclinical data demonstrating that niraparib crosses the blood brain barrier in animal models and highlighting potential genetic markers of resistance in animal models of small cell lung cancer."
http://investorshangout.com/post/view?id=3322617
(0)
(0)Scroll down for more posts ▼
